氣喘和慢性阻塞性肺疾病（COPD）治療藥研發趨勢

氣喘和慢性阻塞性肺疾病（COPD）治療藥研發趨勢 是由出版商Espicom Business Intelligence在2006年08月所出版的。 這份英文市場調查報告書包含96 PAGES 價格從美金2460起跳。

簡介

目錄

Abstract

A fast growing sector with strong products and players - but what will the COPD/Asthma landscape look like 5 years from now?

The global asthma and COPD market is currently worth around US$20 billion. The top twelve pharmaceutical products by value had combined global sales of US$15.7 billion in 2005. Six brands had sales in excess of US$1 billion. Combined sales of the top ten products were 21.1% higher than in 2004.

A number of older therapies, for asthma in particular, are widely available generically and there is fierce competition in the market. The asthma market accounts for the majority of the total and is valued at around US$15 billion. The COPD market is currently valued at US$4 - US$5 billion and is set to double in the next five years.

Future market growth will be driven by increasing disease awareness, an increasing patient pool, both in the paediatric asthma sector and the ageing population susceptible to COPD, and the launch of newer, more expensive therapies targeting areas of high unmet clinical need. These will be offset to some extent by the launch of new generics and the sales erosion of monotherapies by combination products.

This report provides a complete insight to the prospects for companies and products that are driving this high growth US$20 billion sector.

Table of Contents

• Foreword
• Executive Summary
• What are Asthma and COPD?
• Morbidity and Mortality
• Diagnosis and Treatment
• Asthma Management
• COPD Management
• Pharmacotherapy
  • Current Market Leaders
  • Drugs in the Pipeline
  • Competitor Ratio Analysis
• Short-Acting Beta-2 Agonists
  • Xopenex (levalbuterol)
  • Sales Forecast
  • Patent Challenges
  • Clinical Trials
    • Xopenex versus racemic albuterol in COPD
    • Xopenex HFA study
    • Xopenex in the emergency room
• Inhaled Corticosteroids
  • Flixotide/Flovent (fluticasone propionate)
    • Sales Forecasts
    • Clinical Trials
  • Pulmicort (budesonide)
    • Sales Forecast
    • Patent Challenge
    • Clinical Trials
      • START - budesonide during pregnancy
      • START - budesonide in children with mild persistent asthma
      • START - safety outcome data
      • EUROSCOP
      • Long-term data from early intervention study in Finland
  • Asmanex (mometasone furoate)
    • Sales Forecasts and Assumptions
    • Competitor Ratio Analysis
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within marketplace
    • Risks associated with drug development in therapeutic class
  • Clinical Trials
    • Patients previously maintained on bronchodilators alone
    • Patients previously maintained on inhaled corticosteroids
    • Patients previously maintained on oral corticosteroids
  • Alvesco (ciclesonide)
    • Sales Forecast and Assumptions
    • Competitor Ratio Analysis
      • Novelty/rationale for mechanism of action
      • Proof of concept/clinical data
      • Management/clinical expertise
      • Competition within marketplace
      • Risks associated with drug development in therapeutic class
    • Clinical trials
      • Ciclesonide versus fluticasone propionate
      • Low incidence of oropharyngeal side effects
      • Ciclesonide versus budesonide and fluticasone
      • Intranasal formulation
      • Ciclesonide versus budesonide
• Muscarinic Antagonists
  • Spiriva (tiotropium)
    • Sales Forecast and Assumptions
    • Competitor Ratio Analysis
      • Novelty/rationale for mechanism of action
      • Proof of concept/clinical data
      • Management/clinical expertise
      • Competition within marketplace
      • Risks associated with drug development in therapeutic class
  • Clinical Trials
    • Pooled Studies
    • Study on COPD patients in France
    • Spiriva+formoterol versus salmeterol+fluticasone propionate
    • UPLIFT
    • TIPHON
• Combination Therapy
  • Seretide/Advair (salmeterol+fluticasone propionate)
    • Sales Forecasts
    • Patent Challenge
    • Safety Issues
    • Clinical Trials: COPD
      • TORCH
      • TRISTAN
    • Clinical Trials: Asthma
      • Biopsy Study in Moderate Asthma
      • EXCEL
      • GOAL
      • Advair versus montelukast
  • Symbicort (budesonide+formoterol)
    • Sales Forecast
    • European patent challenge
    • Clinical Trials: COPD
      • Calverly et al.
    • Clinical Trials: Asthma
      • SUND
      • STAY
      • Head to head study: Symbicort Turbuhaler versus Seretide (salmeterol+fluticasone)
    • Clinical Trials: Asthma+COPD
      • ASSURE
• Leukotriene Receptor Antagonists
  • Singulair (montelukast)
    • Sales Forecast
    • Clinical Trials
      • PREVIA
• Anti-Immunoglobulin E Therapy
  • Xolair (omalizumab)
    • Sales Forecast and Assumptions
    • Competitor Ratio Analysis
      • Novelty/rationale for mechanism of action
      • Proof of concept/clinical data
      • Management/clinical expertise
      • Competition within marketplace
      • Risks associated with drug development in therapeutic class
    • Clinical Trials
      • Long-term data
      • Pooled study data
• Drugs in Development
• PDE-IV Inhibitors
  • Ariflo (cilomilast)
    • Sales Forecasts and Assumptions
    • Competitor Ratio Analysis
      • Novelty/rationale for mechanism of action
      • Proof of concept/clinical data
      • Management/clinical expertise
      • Competition within marketplace
      • Risks associated with drug development in therapeutic class
    • Clinical trials
  • Daxas (roflumilast)
    • Sales Forecasts and Assumptions
    • Competitor Ratio Analysis
      • Novelty/rationale for mechanism of action
      • Proof of concept/clinical data
      • Management/clinical expertise
      • Competition within marketplace
      • Risks associated with drug development in therapeutic class
    • Clinical Trials
      • Efficacy & safety study in COPD
      • RATIO/M2-112
      • RECORD
      • Other studies
• Long-Acting Beta Agonists
  • Arformoterol
    • Sales Forecasts and Assumptions
    • Competitor Ratio Analysis
      • Novelty/rationale for mechanism of action
      • Proof of concept/clinical data
      • Management/clinical expertise
      • Competition within marketplace
      • Risks associated with drug development in therapeutic class
    • Clinical Trials
  • Indacaterol
    • Sales Forecast and Assumptions
    • Competitor Ratio Analysis
      • Novelty/rationale for mechanism of action
      • Proof of concept/clinical data
      • Management/clinical expertise
      • Competition within marketplace
      • Risks associated with drug development in therapeutic class
    • Clinical Trials
  • GSK 159797
  • Sales Forecasts and Assumptions
  • Competitor Ratio Analysis
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within marketplace
    • Risks associated with drug development in therapeutic class
  • Clinical Trials
• Long-Acting Muscarinic Antagonists
  • NVA237
    • Sales Forecast and Assumptions
    • Competitor Ratio Analysis
      • Novelty/rationale for mechanism of action
      • Proof of concept/clinical data
      • Management/clinical expertise
      • Competition within marketplace
      • Risks associated with drug development in therapeutic class
    • Clinical Trials
• SOURCES
• Espicom Sources
• Others

相關商品

藥物開發相關市場調查報告書

乳癌，肺癌，血管新生:藥物開發策略分析
Triple Analysis: Breast Cancer, Lung Cancer and Angiogenesis
價格 : US $ 5175
出版日期 : 2012年01月

大腸癌，肺癌，血管新生:藥物開發策略分析
Triple Analysis: Colorectal Cancer, Lung Cancer and Angiogenesis
價格 : US $ 5175
出版日期 : 2012年01月

白血病，肺癌，血管新生:藥物開發策略分析
Triple Analysis: Leukemia, Lung Cancer and Angiogenesis
價格 : US $ 5175
出版日期 : 2012年01月

Espicom Business Intelligence發行的製藥相關市場調查報告書

疼痛治療藥市場的發展：侵害受容性及神經性疼痛治療藥的開發

Evolution in the Pain Therapy Drugs Market: Nociceptive and Neuropathic Drug Development

價格 : US $ 2265

出版日期 : 2012年01月

世界非專利藥品市場

World Generic Markets

價格 : US $ 1080

出版日期 : 2012年01月

全球醫藥品市場展望

The Outlook for Pharmaceuticals Worldwide

價格 : US $ 17490

出版日期 : 2012年01月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!